Tarlatamab
An editor has performed a search and found that sufficient sources exist to establish the subject's notability. (January 2024) |
Monoclonal antibody | |
---|---|
Type | ? |
Clinical data | |
Other names | AMG757; AMG-757 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
Tarlatamab is a bispecific T cell engager that binds DLL3 and CD3 which has shown promise for previously treated small cell lung cancer.[1]
References[edit]
- ^ Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. (November 2023). "Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer". The New England Journal of Medicine. 389 (22): 2063–2075. doi:10.1056/NEJMoa2307980. PMID 37861218.